Literature DB >> 8205259

Serum carboxy-terminal propeptide of human type I procollagen in patients with primary hyperparathyroidism: studies in basal conditions and after parathyroid surgery.

S Minisola1, E Romagnoli, L Scarnecchia, R Rosso, M T Pacitti, A Scarda, G Mazzuoli.   

Abstract

This study was carried out in order to evaluate serum carboxy-terminal propeptide of human type I procollagen (PICP) in patients with primary hyperparathyroidism and to examine its changes following parathyroidectomy. Seventeen patients (four males and 13 famels, aged 53.8 +/- 3.1 SEM years) were studied in basal conditions; six patients also were investigated after successful parathyroid surgery. Mean serum PICP values of patients with primary hyperparathyroidism (194.5 +/- 27 SEM micrograms/l) were significantly higher (p < 0.001) with respect to those found in normal subjects. However, deviations from the norm (Z score values) were significantly less with respect to deviations of serum osteocalcin, alkaline phosphatase and urinary hydroxyproline/creatinine ratio. Following parathyroidectomy, it was possible to observe a discrepancy between markers of bone resorption and those of bone formation. The former tend to decrease, while the latter either do not show any significant change (serum alkaline phosphatase and serum osteocalcin) or increase (serum procollagen). The results of our investigation indicate that in basal conditions the assay of serum procollagen may be of clinical value but it would be better to use it in combination with other biomarkers of skeletal remodelling. The results obtained after parathyroidectomy are the opposite of those obtained following parathyroid hormone infusion and should be ascribed to the effect of acute hormone deficiency on collagen synthesis. The positive biochemical uncoupling following surgery might lend support to the rise of bone mineral density consistently reported in the first few months following parathyroidectomy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8205259     DOI: 10.1530/eje.0.1300587

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  3 in total

1.  Emerging data on cardiovascular risk in primary hyperparathyroidism.

Authors:  Jessica Pepe; Sara Piemonte; Cristiana Cipriani; Mirella Cilli; Salvatore Minisola
Journal:  Endocrine       Date:  2014-09-10       Impact factor: 3.633

2.  Hypovitaminosis D in primary hyperparathyroidism: to treat or not to treat? That is the question.

Authors:  Salvatore Minisola; Elisabetta Romagnoli; Alfredo Scillitani; Sudhakar D Rao
Journal:  J Endocrinol Invest       Date:  2014-03-20       Impact factor: 4.256

3.  The measurement of urinary amino-terminal telopeptides of type I collagen to monitor bone resorption in patients with primary hyperparathyroidism.

Authors:  S Minisola; M T Pacitti; R Rosso; C Pellegrino; E Ombricolo; D Pisani; E Romagnoli; C Damiani; G Aliberti; A Scarda; S F Mazzuoli
Journal:  J Endocrinol Invest       Date:  1997-10       Impact factor: 4.256

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.